Inflammatory Bowel Diseases
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus.
25:1-13.
2019
-
The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease.
24:1619-1623.
2018
-
Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD.
23:1950-1961.
2017
-
Systematic Review and Meta-analysis.
23:1702-1709.
2017
-
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis..
23:1702-1709.
2017
-
Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011.
23:868-874.
2017
-
Development of the IBD Disk.
23:333-340.
2017
-
The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease.
23:181-191.
2017
-
Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies).
22:1239-1245.
2016
-
New Applications for Traditional Drugs in Inflammatory Bowel Disease.
21:2948-2957.
2015
-
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model.
21:1883-1893.
2015
-
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohnʼs Disease.
21:1-1.
2015
-
Systematic Review.
21:1683-1694.
2015
-
Briakinumab for Treatment of Crohnʼs Disease.
21:1-1.
2015
-
Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing.
21:606-614.
2015
-
Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease.
20:1862-1869.
2014
-
AST-120 (Spherical Carbon Adsorbent) in the Treatment of Perianal Fistulae in Mild-to-Moderate Crohnʼs Disease.
20:872-881.
2014
-
The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models.
20:417-430.
2014
-
Hepatotoxicity Caused by Methotrexate Therapy in Children with Inflammatory Bowel Disease.
20:47-59.
2014
-
Reduced Fat Oxidation Rates During Submaximal Exercise in Adolescents with Crohnʼs Disease.
19:2659-2665.
2013
-
52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants.
19:1700-1709.
2013
-
Mucosal Improvement in Patients With Moderate to Severe Postoperative Endoscopic Recurrence of Crohn’s Disease and Azathioprine Metabolite Levels.
19:590-598.
2013
-
Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohnʼs Disease.
19:293-300.
2013
-
Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes.
19:332-341.
2013
-
IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis.
19:115-123.
2013
-
Commensal and Probiotic Bacteria Influence Intestinal Barrier Function and Susceptibility to Colitis in Nod1−/−;Nod2−/− Mice.
18:1434-1446.
2012
-
Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study.
18:212-218.
2012
-
Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies.
18:201-211.
2012
-
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE.
18:1-9.
2012
-
Are inherited thrombotic risk factors associated with fibrostenosis in Crohnʼs disease?.
17:2505-2511.
2011
-
Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease.
17:1451-1463.
2011
-
Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile.
17:1540-1546.
2011
-
Development of the Crohnʼs disease digestive damage score, the Lémann score.
17:1415-1422.
2011
-
IL-10RA truncation mutations and semite populations.
17:1438-1438.
2011
-
Pediatric modification of the Montreal classification for inflammatory bowel disease.
17:1314-1321.
2011
-
Assessment of knowledge in adolescents with inflammatory bowel disease using a novel transition tool.
17:1131-1137.
2011
-
IBD Around the world: Comparing the epidemiology, diagnosis, and treatment.
17:639-644.
2011
-
Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases.
17:84-90.
2011
-
Assessing disease activity in ulcerative colitis.
16:651-656.
2010
-
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis†.
16:620-629.
2010
-
Endoscopy and MR enteroclysis: Equivalent tools in predicting clinical recurrence in patients with Crohnʼs disease after ileocolic resection.
16:198-203.
2010
-
Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
16:233-242.
2010
-
Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.
15:985-996.
2009
-
Extracorporeal photopheresis for the treatment of refractory Crohnʼs disease: Results of an open-label pilot study.
15:829-836.
2009
-
Are there epidemiological differences between crohnʼs disease and ulcerative colitis?.
14:S1-S1.
2008
-
Which patients with IBD need psychological interventions? A controlled study.
14:1273-1280.
2008
-
CARD15 and IL23R influences Crohnʼs disease susceptibility but not disease phenotype in a Brazilian population.
14:674-679.
2008
-
Intestinal epithelial barrier dysfunction and dendritic cell redistribution during early stages of inflammation in the rat: Role for TLR-2 and -4 blockage.
14:632-644.
2008
-
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
13:1135-1140.
2007
-
Complications in Crohnʼs disease: Right-sided ureteric stenosis and hydronephrosis.
13:1056-1057.
2007
-
Impact of interobserver disagreement on phenotype–genotype associations in Crohnʼs disease.
13:156-163.
2007
-
Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation.
12:457-470.
2006
-
Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health.
12:38-46.
2006
-
Positron Emission Tomography in the Investigation of Pediatric Inflammatory Bowel Disease.
11:733-738.
2005
-
Assessing the Demand for Psychological Care in Chronic Diseases.
10:637-645.
2004
-
Infliximab.
10:36-40.
2004
-
All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Pro.
7:158-162.
2001
-
Well-Adjusted Children: An Alternate View of Children with Inflammatory Bowel Disease and Functional Gastrointestinal Complaints.
6:1-7.
2000
-
Bone Mineral Metabolism In Pediatric Inflammatory Bowel Disease.
5:192-199.
1999
-
“Immune/Non-Immune Cell Interactions in Intestinal Inflammation” Workshop.
3:133-141.
1997
-
“Immune/non-immune cell interactions in intestinal inflammation” workshop.
3:133-141.
1997
-
HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN'S DISEASE: RESULTS FROM FITZROY STUDY
2018
-
HISTOLOGICAL AND ENDOSCOPIC HEALING AFTER QBECO TREATMENT IN AN OPEN-LABEL PHASE 2 STUDY IN PATIENTS WITH ULCERATIVE COLITIS
2018
-
Allied Health Professional Support in Pediatric Inflammatory Bowel Disease: A Survey from the Canadian Pediatric IBD Network
2017
-
Early Use of Therapeutic Drug Monitoring to Individualize Infliximab Therapy in Paediatric IBD, a Multicentre Prospective Study
2017
-
Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis
2017
-
Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-analysis
2016
-
Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis
2016
-
P-064 Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohnʼs Disease in Remission
2016
-
P-079 YI The Association Between Anxiety and Depression and Health Related Quality of Life in Patients with Inflammatory Bowel Disease (IBD)
2016
-
P-231 YI Patient Experience Living with Inflammatory Bowel Disease
2016
-
Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies
2012
-
Does Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease Impact Clinical Management? A Canadian Experience.
2012
-
Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT-SC Induction
2012
-
Validation and Comparison of Algorithms to Identify Adult-Onset Inflammatory Bowel Disease Patients From Within Health Administrative Data
2012
-
Development of a specialist nurse educational program: The NIICE (Nurses Initiative in IBD Care and Education) in Canada Program
2011
-
Evolution of the phenotypic characteristics of pediatric Inflammatory Bowel Disease using the Paris classification
2011
-
Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis
2011
-
Interdisciplinary, prompt access IBD clinic: The hamilton health science experience
2011
-
PYRAMID registry: An observational study of adalimumab in Crohnʼs disease: results at year 3
2011
-
A post-hoc analysis: Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of corticosteroid-free state and corticosteroid-free symptomatic remission
2011
-
Adalimumab induction therapy improves health-related quality of life in patients with moderately to severely active ulcerative colitis.
2011
-
Adalimumab is effective for inducing clinical remission at week 4 regardless of baseline corticosteroid use: Pooled analysis of 4 clinical trials.
2011
-
Effect of adalimumab induction therapy on clinical laboratory parameters suggesting improved nutrition and inflammation status in patients with moderately to severely active ulcerative colitis.
2011
-
Exploring the reliability of phenotypic assignment for pediatric inflammatory bowel disease.
2011
-
PYRAMID Registry: Observational study of adalimumab in Crohn's disease at year 2.
2011
-
Safety of adalimumab in global clinical trials of patients with Crohn's disease.
2011
-
Adalimumab Therapy reduces the presence of Extraintestinal Manifestations in patients with Crohnʼs Disease: The CARE Trial
2009
-
SONIC Study. A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy
2009
-
Severe neutropenia following a single infliximab infusion in a child with Crohn disease
2009
-
Sustained Mucosal Healing in Adalimumab-Treated patients with moderate to severe Ileocolonic Crohnʼs Disease: Results of the EXTEND Trial
2009
-
Infliximab-induced psoriasis in pediatric Crohn Disease; Experience of this paradoxical event at a tertiary centre
2008
-
Life threatening complications of sulphasalazine therapy in pediatric inflammatory bowel disease
2008
-
Response to Adalimumab Therapy in bio-naive patients and in Infliximab nonresponders: Results of a Phase Illb Clinical Trial
2008
-
SONIC: A randomized, double-blind, controlled trial comparing Infliximab and Infliximab plus Azathioprine to Azathioprine in patients with Crohn's Disease naive to immunomodulators and biologic therapy
2008
-
Safety of Adalimumab in patients with Crohn's Disease: Analysis of global clinical trials
2008
-
Discontinuation of immunomodulator therapy in infliximab-treated children with Crohn disease; one year outcome evaluating influences on disease activity and infliximab antibody formation
2008
-
Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2
2008
-
Improvement in health related quality of life in infliximab-treated moderate-tosevere active ulcerative colitis patients: Improvement overall and by baseline disease activity
2007
-
Association Between NOD2/CARD15 Gene Variants and Response to Antibiotics in Perianal Fistulizing Crohn's Disease
2006
-
The Vagus Nerve
2006
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)